Throughout his career, Michael has worked in Quality, Operations, and Manufacturing, showcasing expertise in monoclonal antibodies, small molecules, medical devices, and advanced therapies. His notable roles include serving as Senior Vice President of Cell Therapy Manufacturing at Nurix and Global Head of Quality at Adaptimmune.

Michael's biotech journey began at IDEC Pharmaceuticals, where he developed downstream processing methodologies for Rituxan. He has contributed significantly to Eli Lilly, Millennium Pharmaceuticals, and Biomarin.

In addition to his corporate achievements, Michael has been actively engaged with the PDA, serving as a past Board Member, where he co-founded and serves as  past chair of the ATMP Advisory Board. He co-founded the ATMP Interest Group and contributed to several PDA Technical Reports, white papers, and regulatory comment requests. Michael's leadership and contributions underscore his commitment to advancing the biopharmaceutical industry.